Cost‐effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non‐small cell lung cancer

Author:

Buja Alessandra1ORCID,Pasello Giulia23,Schiavon Marco1,De Luca Giuseppe1,Rivera Michele1,Cozzolino Claudia4,De Polo Anna1,Scioni Manuela5,Bortolami Alberto6,Baldo Vincenzo1,Conte PierFranco23ORCID

Affiliation:

1. Department of Cardiac, Thoracic, and Vascular Sciences and Public Health University of Padua Padua Italy

2. Department of Surgery Oncology and Gastroenterology, University of Padua Padua Italy

3. Medical Oncology 2 Veneto Institute of Oncology IOV‐IRCCS Padua Italy

4. Surgical Oncology Unit Veneto Institute of Oncology IOV‐IRCCS Padua Italy

5. Statistics Department University of Padua Padua Italy

6. Rete Oncologica Veneta (ROV) Veneto Institute of Oncology IOV‐IRCCS Padua Italy

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Reference40 articles.

1. Lung Cancer Statistics

2. Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey

3. The financial hazard of personalized medicine and supportive care

4. NCCN.NCCN non‐small‐lung‐cancer guidelines. Available athttps://www.nccn.org/professionals/physician_gls/default.aspx. Accessed December 6 2021.

5. GUIDA NEOPLASIE del POLMONE;LINEE;AIOM,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3